Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023

SELL
$108.51 - $130.22 $560,128 - $672,195
-5,162 Reduced 99.48%
27 $3,000
Q2 2023

Aug 04, 2023

BUY
$78.48 - $130.32 $407,232 - $676,230
5,189 New
5,189 $609,000
Q2 2022

Aug 03, 2022

SELL
$48.93 - $73.47 $1,272 - $1,910
-26 Closed
0 $0
Q1 2022

May 02, 2022

SELL
$51.99 - $72.11 $259,898 - $360,477
-4,999 Reduced 99.48%
26 $1,000
Q3 2021

Oct 28, 2021

SELL
$52.01 - $71.77 $26,005 - $35,885
-500 Reduced 9.05%
5,025 $360,000
Q2 2021

Aug 12, 2021

BUY
$62.14 - $81.82 $343,323 - $452,055
5,525 New
5,525 $375,000
Q4 2020

Feb 02, 2021

SELL
$40.64 - $61.38 $50,027 - $75,558
-1,231 Closed
0 $0
Q3 2020

Oct 14, 2020

BUY
$37.76 - $48.49 $44,141 - $56,684
1,169 Added 1885.48%
1,231 $52,000
Q2 2020

Jul 13, 2020

BUY
$37.03 - $60.0 $2,295 - $3,720
62 New
62 $2,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.81B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.